The use of the R6 transgenic mouse models of Huntington' s disease in attempts to develop novel therapeutic strategies

183Citations
Citations of this article
323Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Huntington's disease (HD) is a genetic neurodegenerative disorder. Since identification of the disease-causing gene in 1993, a number of genetically modified animal models of HD have been generated. The first transgenic mouse models, R6/1 and R6/2 lines, were established 8 years ago. The R6/2 mice have been the best characterized and the most widely used model to study pathogenesis of HD and therapeutic interventions. In the present review, we especially focus on the characteristics of R6 transgenic mouse models and, in greater detail, describe the different therapeutic strategies that have been tested in these mice. We also, at the end, critically assess the relevance of the HD mouse models compared with the human disease and discuss how they can be best used in the future. © The American Society for Experimental NeuroTherapeutics, Inc.

Cite

CITATION STYLE

APA

Li, J. Y., Popovic, N., & Brundin, P. (2005). The use of the R6 transgenic mouse models of Huntington’ s disease in attempts to develop novel therapeutic strategies. NeuroRx, 2(3), 447–464. https://doi.org/10.1602/neurorx.2.3.447

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free